Combination of a Mcl-1 inhibitor and a standard of care treatment for hematologic cancers, uses and pharmaceutical compositions thereof
A combination comprising a Mcl-1 inhibitor and a second anticancer agent, wherein the second anticancer agent is selected from anthracyclines, cytarabine and hypomethylating agents, and compositions and uses thereof.
Saved in:
Main Authors | , , , , |
---|---|
Format | Patent |
Language | English |
Published |
30.05.2024
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | A combination comprising a Mcl-1 inhibitor and a second anticancer agent, wherein the second anticancer agent is selected from anthracyclines, cytarabine and hypomethylating agents, and compositions and uses thereof. |
---|---|
Bibliography: | Application Number: AU20180288520 |